| JXHL1600100 | 奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2016-08-31 | AstraZeneca AB | AstraZeneca AB | Certificate Issued | 2017-01-20 | view |
| JXHL1600101 | 奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2016-08-31 | AstraZeneca AB | AstraZeneca AB | Certificate Issued | 2017-01-20 | view |
| JXHS1700005 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2017-02-03 | AstraZeneca AB | AstraZeneca AB | Certificate Issued | 2017-03-24 | view |
| JXHS1700006 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2017-02-03 | AstraZeneca AB | AstraZeneca AB | Certificate Issued | 2017-03-24 | view |
| JYHB1701075 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs | Supplementary Application | 2017-08-21 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-02-13 | view |
| JYHB1701074 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs | Supplementary Application | 2017-08-21 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-02-13 | view |
| JYHB1701518 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2017-12-01 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Filed | 2017-12-20 | view |
| JYHB1701519 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2017-12-01 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Filed | 2017-12-20 | view |
| JYHB1800013 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2018-01-12 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Approval Completed-Pending Certificated | 2018-02-01 | view |
| JYHB1800012 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2018-01-12 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Approval Completed-Pending Certificated | 2018-02-01 | view |
| JYHF1800014 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs | Supplementary Application | 2018-02-07 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-03-06 | view |
| JYHF1800015 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs | Supplementary Application | 2018-02-07 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-03-06 | view |
| JXHL1800076 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(2.4) | Import Drug Application | 2018-07-09 | | AstraZeneca AB | Certificate Issued | 2018-09-04 | view |
| JXHL1800075 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(2.4) | Import Drug Application | 2018-07-09 | | AstraZeneca AB | Certificate Issued | 2018-09-04 | view |
| JYHB1800902 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2018-08-01 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-10-10 | view |
| JYHB1800901 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Supplementary Application | 2018-08-01 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2018-10-10 | view |
| JXHS1800054 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2018-10-29 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2019-09-03 | view |
| JXHS1800055 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(5.1) | Import Drug Application | 2018-10-29 | 阿斯利康投资（中国）有限公司 | Astrazeneca Investment (China) Co Ltd | Certificate Issued | 2019-09-03 | view |
| JXHL1900321 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(2.4) | Import Drug Application | 2019-11-22 | | AstraZeneca AB | In Review | 2019-11-21 | view |
| JXHL1900320 | 甲磺酸奥希替尼片 | osimertinib mesylate | Tablet | Chemical Drugs(2.4) | Import Drug Application | 2019-11-22 | | AstraZeneca AB | In Review | 2019-11-21 | view |
